Dr. Mark Sutherland
Information about Dr. Mark Sutherland at the University of Bradford.
Some details are missing for this profile, including contact information. If this is your profile, please review guidance on how to report this issue.
Biography
Dr Mark Sutherland is a Lecturer in Biochemistry in the School of Chemistry and Biosciences, University of Bradford. After completing his MSc in Microbiology at the University of Stellenbosch, South Africa he worked for a few years as a school teacher and University Lecturer. He was offered a PhD at the Charite â Campus Benjamin Franklin, Berlin, Germany where he received his doctorate in Medical Biochemistry. He then worked for a number of years as a PDRA in Berlin in the field of immunotoxins. This work resulted in a number of publications, review articles and book chapters. In 2005 he moved to the Institute of Cancer Therapeutics at the University of Bradford. He carried out research for a number of projects within the Institute to generate proof-of-concept data for grant and patent applications. He also taught laboratory skills to MSc and PhD students, and lectured undergraduate and MSc students. His research was in the field of integrins as a target for new anti-cancer drugs in prostate cancer and melanoma, as well as the role of sialyltransferases in neuroblastoma. The research involves a wide range of methodologies including generating lentivirus knockout models (shRNA), development of an ELISA for biomarker analysis, protein expression/purification using GST-tagged protein in E.coli and luciferase reporter assays. This work has led to numerous publications, and successful grant applications. Dr Sutherland has vast experience in an array of Molecular Biology techniques including gene cloning, transformation/transfection, Western blotting, PCR and qPCR; as well as managing the Molecular Biology Laboratory. He started his current role as Lecturer in January 2019.
Professional activities
Information about education, employment and areas of particular interest for Dr. Mark Sutherland is as follows:
- Faculty of Life Sciences Genetically Modified Organisms, in the year 2014 (specified as 01/01/2014)
Education
- Charite Campus Benjamin Franklin - PhD (rer med)
- University of Stellenbosch, South Africa - MSc
- University of Stellenbosch, South Africa - BSc (Hon)
- University of Cape Town, South Africa - BSc
- German
Employment
- University of Bradford - Senior Experimental Officer in the year 2005 (specified as 01/11/2005)
- Charite - Klinikum Benjamin Franklin - PDRA in the year 2000 (specified as 01/11/2000)
- University of Fort Hare, South Africa - Lecturer in Biochemistry and Microbiology in the year 1995 (specified as 01/01/1995)
- Cape Education Departmant - Science and Mathematics teacher in the year 1994 (specified as 01/01/1994)
- University of Stellenbosch, South Africa - Research Assistant in the year 1993 (specified as 01/01/1993)
Publications
There are 30 publications involving or that are attributed to Dr. Mark Sutherland. They are listed as:
- book chapter (1)
- peer reviewed journal (26)
- reviews (3)
Book Chapter
Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
---|---|---|---|---|---|---|---|---|---|---|---|
Preclinical Studies of Saponins for Tumor Therapy | 2015 | Recent Advances in Medicinal Chemistry | Recent Advances in Medicinal Chemistry | 1 | 272 - 302 | Bachran C.;Bachran S.;Sutherland M.;Bachran D.;Fuchs H. | 9780128039618 | 10.1016/B978-0-12-803961-8.50009-9 |
Peer Reviewed Journal
Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
---|---|---|---|---|---|---|---|---|---|---|---|
Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy | 2024 | International Journal of Molecular Sciences | 25 | Asiye Busra Boz Er;Helen M Sheldrake;Mark Sutherland | 10.3390/ijms25147946 | ||||||
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy | 2023 | Cancers | 15 | Mark Sutherland, Andrew Gordon, Fatemah OFO Al-Shammari, Adam Throup, Amy Cilia La Corte, Helen Philippou, Steven D Shnyder, Laurence H Patterson, Helen M Sheldrake | https://doi.org/10.3390/cancers15164023 | ||||||
Matrix metalloproteinase 2 is a target of the RAN-GTP pathway and mediates migration, invasion and metastasis in human breast cancer. | 2022 | Life Sciences | 310 | El-Tanani M;Platt-Higgins A;Lee YF;Al Khatib AO;Haggag Y;Sutherland M;Zhang SD;Aljabali AAA;Mishra V;Serrano-Aroca Á;Tambuwala MM;Rudland PS; | 1879-0631 | 10.1016/j.lfs.2022.121046 | |||||
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
Exploring and Exploiting Acceptor Preferences of the Human Polysialyltransferases as a Basis for an Inhibitor Screen | 2017 | ChemBioChem | 18 | 1332 - 1337 | Ehrit, J.; Keys, T.G.; Sutherland, Mark H.; Wolf, S.; Meier, C.; Falconer, R.A.; Gerardy-Schahn, R. | 10.1002/cbic.201700157 | |||||
An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity | 2016 | ANALYST (PRINT) | 141 | 5849 - 5856 | Elkashef, Sara M.; Sutherland, Mark H.; Patterson, Laurence H.; Loadman, Paul M.; Falconer, Robert A. | 10.1039/c6an01073c | |||||
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue | 2015 | MedChemComm | 6 | 187 - 191 | Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus | dx.doi.org/10.1039/c4md00411f | |||||
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder | 2013 | Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H. | |||||||||
Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration | 2013 | PLoS ONE | 8 | e73366 | Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. | 10.1371/journal.pone.0073366 | |||||
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity | 2013 | Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus | |||||||||
A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin | 2011 | Life Sciences | 88 | 226 - 232 | Bachran C.;Schneider S.;Riese S.;Bachran D.;Urban R.;Schellmann N.;Zahn C.;Sutherland M.;Fuchs H. | 0024-3205 | 10.1016/j.lfs.2010.11.012 | ||||
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity | 2011 | Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H. | |||||||||
Improved preparation and detection of cytochrome P450 isoforms using MS methods | 2010 | Proteomics | 10 | 327 - 331 | Sutton C.;Sutherland M.;Shnyder S.;Patterson L. | 1615-9853 | 10.1002/pmic.200900489 | ||||
Quantification of diphtheria toxin-mediated ADP-ribosylation in a solid-phase assay | 2007 | Clinical Chemistry | 53 | 1676 - 1683 | Bachran C.;Sutherland M.;Bachran D.;Fuchs H. | 0009-9147 | 10.1373/clinchem.2007.085365 | ||||
The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure | 2006 | Experimental Biology and Medicine | 231 | 412 - 420 | Bachran C.;Sutherland M.;Heisler I.;Hebestreit P.;Melzig M.;Fuchs H. | 1535-3702 | 10.1177/153537020623100407 | ||||
Saponins as tool for improved targeted tumor therapies. | 2009 | Current Drug Targets | 10 | Fuchs H;Bachran D;Panjideh H;Schellmann N;Weng A;Melzig MF;Sutherland M;Bachran C; | 1873-5592 | 10.2174/138945009787354584 | |||||
Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way. | 2009 | Journal of immunotherapy (Hagerstown, Md. : 1997) | 32 | Bachran C;Dürkop H;Sutherland M;Bachran D;Müller C;Weng A;Melzig MF;Fuchs H; | 1537-4513 | 10.1097/CJI.0b013e3181ad4052 | |||||
Saponins in tumor therapy. | 2008 | Mini-Reviews in Medicinal Chemistry | 8 | Bachran C;Bachran S;Sutherland M;Bachran D;Fuchs H; | 1389-5575 | 10.2174/138955708784534445 | |||||
A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. | 2007 | Journal of Controlled Release | 117 | Fuchs H;Bachran C;Li T;Heisler I;Dürkop H;Sutherland M; | 0168-3659 | 10.1016/j.jconrel.2006.11.019 | |||||
Patents on immunotoxins and chimeric toxins for the treatment of cancer. | 2007 | Recent Patents on Drug Delivery and Formulation | 1 | Bachran C;Sutherland M;Bachran D;Fuchs H; | 2212-4039 | 10.2174/187221107780831932 | |||||
Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. | 2005 | Journal of Controlled Release | 106 | Heisler I;Sutherland M;Bachran C;Hebestreit P;Schnitger A;Melzig MF;Fuchs H; | 0168-3659 | 10.1016/j.jconrel.2005.04.006 | |||||
Influence of protein transduction domains on target-specific chimeric proteins. | 2005 | Biochemical and Biophysical Research Communications | 337 | Bachran C;Heisler I;Fuchs H;Sutherland M; | 0006-291X | 10.1016/j.bbrc.2005.09.095 | |||||
A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. | 2003 | International Journal of Cancer | 103 | Heisler I;Keller J;Tauber R;Sutherland M;Fuchs H; | 0020-7136 | 10.1002/ijc.10809 | |||||
A colorimetric assay for the quantitation of free adenine applied to determine the enzymatic activity of ribosome-inactivating proteins. | 2002 | Analytical Biochemistry | 302 | Heisler I;Keller J;Tauber R;Sutherland M;Fuchs H; | 0003-2697 | 10.1006/abio.2001.5527 | |||||
Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism. | 2001 | Biochemical Journal | 353 | Sutherland M;Shankaranarayanan P;Schewe T;Nigam S; | 0264-6021 | ||||||
Metabolic suppression of platelet-type 12-lipoxygenase in human uterine cervix with invasive carcinoma. | 1999 | International Journal of Cancer | 82 | Nigam S;Kumar GS;Sutherland M;Schewe T;Ikawa H;Yamasaki Y;Ueda N;Yamamoto S; | 0020-7136 | 10.1002/(sici)1097-0215(19990909)82:6<827::aid-ijc10>3.0.co;2-q |
Reviews
Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
---|---|---|---|---|---|---|---|---|---|---|---|
RGD-binding integrins in prostate cancer: Expression patterns and therapeutic prospects against bone metastasis | 2012 | Cancers | 4 | 1106 - 1145 | Sutherland M.;Gordon A.;Shnyder S.;Patterson L.;Sheldrake H. | 2072-6694 | 10.3390/cancers4041106 | ||||
Saponins as tool for improved targeted tumor therapies | 2009 | Current Drug Targets | 10 | 140 - 151 | Fuchs H.;Bachran D.;Panjideh H.;Schellmann N.;Weng A.;Melzig M.;Sutherland M.;Bachran C. | 1389-4501 | 10.2174/138945009787354584 | ||||
Saponins in tumor therapy | 2008 | Mini-Reviews in Medicinal Chemistry | 8 | 575 - 584 | Bachran C.;Bachran S.;Sutherland M.;Bachran D.;Fuchs H. | 1389-5575 | 10.2174/138955708784534445 |